Bone Biologics Corp
BBLGWDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Risedronate
Osteoporosis
Core decompression/PREOB® implantation
Avascular Necrosis of Femur Head
Trabectedin
Soft Tissue Sarcoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Risedronate | Phase 3 | Osteoporosis | - | - |
Core decompression/PREOB® implantation | Phase 2 | Avascular Necrosis of Femur Head | - | - |
Trabectedin | Phase 2 | Soft Tissue Sarcoma | - | - |
Frequently asked questions
What is in Bone Biologics Corp's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Bone Biologics Corp's (BBLGW) pipeline across Phase 3, Phase 2. Its lead program is Risedronate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bone Biologics Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Bone Biologics Corp (BBLGW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BBLGW biotech catalysts?→
Add BBLGW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bone Biologics Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.